Therefore, it seems that targeting ATF3 as a potential novel intervention through gene therapy or other therapeutic approaches could be a promising strategy to attenuate NF-κB up-regulation in cervical cancer. The gene discussed is NFKB1; the disease is cervical carcinoma.